These results fully demonstrate that conjugate I is able to activate the STING pathway in a reduction-dependent manner, coincident with the properties of PtIV prodrugs, and may have fewer side effects from unwanted overactivation of the STING pathway in immune cells far away from the tumor. The gene discussed is STING1; the disease is neoplasm.